Evidence map›Paper›PMID 30632656›Full record

Trial reportEuropean journal of heart failure2019

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.

Maurice Beghetti, Richard N Channick, Kelly M Chin, Lilla Di Scala, Sean Gaine, Hossein-Ardeschir Ghofrani, Marius M Hoeper, Irene M Lang, Vallerie V McLaughlin, Ralph Preiss and 5 more

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Selexipag in patients with complex or uncorrected congenital heart disease: Single centre experience.International journal of cardiology. Congenital heart disease · 2022
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. New developments in adult congenital heart disease.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2020
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 14 institutions in 9 countries.

Maurice BeghettiPediatric Cardiology Unit, Centre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pédiatrique, University of Geneva and Lausanne, Lausanne, Switzerland.
Richard N ChannickDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Kelly M ChinDivision of Internal Medicine, University of Texas Southwestern, Dallas, TX, USA.
Lilla Di ScalaActelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Sean GaineNational Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
Hossein-Ardeschir GhofraniUniversity of Giessen and Marburg Lung Center, Giessen, Germany, member of the German Center of Lung Research, and Department of Medicine, Imperial College London, London, UK.
Marius M HoeperDepartment of Respiratory Medicine, Hannover Medical School and German Centre for Lung Research, Hannover, Germany.
Irene M LangDepartment of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
Vallerie V McLaughlinDepartment of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Ralph PreissActelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Lewis J RubinDepartment of Medicine, University of California, San Diego, CA, USA.
Gérald SimonneauAPHP, Centre de Référence de l'Hypertension Pulmonaire, Service de Pneumologie et Soins Intensifs, CHU Bicêtre, Université Paris-Sud, Le Kremlin-Bicêtre, Paris, France.
Olivier SitbonAPHP, Centre de Référence de l'Hypertension Pulmonaire, Service de Pneumologie et Soins Intensifs, CHU Bicêtre, Université Paris-Sud, Le Kremlin-Bicêtre, Paris, France.
Victor F TapsonDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Nazzareno GalièDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, Italy.
Actelion (Switzerland) · CHBicêtre Hospital · FRCedars-Sinai Medical Center · USImperial College London · GBMater Misericordiae Hospital · AUMedical University of Vienna · ATMedizinische Hochschule Hannover · DEThe University of Texas Southwestern Medical Center · USUniversité Paris-Sud · FRUniversity of Bologna · ITUniversity of California, Los Angeles · USUniversity of California, San Diego · USUniversity of Geneva · CHVA Ann Arbor Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsPatients with pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH) after defect correction have a poor prognosis compared with other CHD-PAH patients. Therefore, it is important that these patients are treated as early and effectively as possible. Evidence supporting the use of PAH therapies in patients with corrected CHD-PAH from randomised controlled trials is limited. The purpose of these analyses was to characterise the corrected CHD-PAH patients from the GRIPHON study and examine the response to selexipag. METHODS AND

resultsOut of the 110 patients diagnosed with corrected CHD-PAH, 55 had atrial septal defects, 38 had ventricular septal defects, 14 had persistent ducti arteriosus, and 3 had defects not further specified. Hazard ratios (HR) and 95% confidence intervals (CI) for the primary composite endpoint were calculated using Cox proportional hazard models. Compared with the non-CHD patients from GRIPHON, patients with corrected CHD-PAH were slightly younger, with a greater proportion being treatment-naive and in World Health Organization functional class I/II. The rate of the primary composite endpoint of morbidity/mortality was lower in patients with corrected CHD-PAH who were treated with selexipag compared with those treated with placebo (HR 0.58; 95% CI 0.25, 1.37). The most common adverse events were those known to be related to selexipag.

conclusionsThese post-hoc analyses of GRIPHON provide valuable information about a large population of patients with corrected CHD-PAH, and suggest that selexipag may delay disease progression and was well-tolerated in patients with corrected CHD-PAH.

Indexed as

AcetamidesCardiac Surgical ProceduresHeart Defects, CongenitalHypertension, PulmonaryPyrazinesAdultAntihypertensive AgentsDisease ProgressionDouble-Blind MethodDrug MonitoringEarly Medical InterventionFemaleHumansMaleMiddle AgedProportional Hazards ModelsAcetamidesAntihypertensive AgentsPyrazinesselexipagCongenital heart diseaseDisease progressionEfficacyPulmonary arterial hypertensionRandomised controlled trialSelexipag

Identifiers

PMID30632656
PMCPMC6607487
OpenAlexW2910609445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.